Prevention and management of major side effects of targeted agents in breast cancer
- 3 September 2010
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 84, e79-e85
- https://doi.org/10.1016/j.critrevonc.2010.07.014
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Skin toxicities of targeted therapiesEuropean Journal of Cancer, 2009
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941Cancer Cell, 2009
- Selectivity and therapeutic inhibition of kinases: to be or not to be?Nature Immunology, 2009
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast CancerJournal of Clinical Oncology, 2008
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100Journal of Clinical Oncology, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerThe New England Journal of Medicine, 2007
- Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapyBritish Journal of Cancer, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987